Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

ACADIA Pharmaceuticals Inc. (ACAD) Soars On Hedge Fund Investment

Page 1 of 2

One of the best ways that retail investors can try to decide which stocks will make for a promising investment is to look at what the hedge funds are doing. This can be achieved by examining a few official filings such as 13F, 13D, and 13G reports. 13F filings are done quarterly and show which positions hedge funds have taken. 13D and 13G reports are done more often, but only when a fund has taken a position of at least 5%. On Thursday, June 6, 2013, a popular biotechnology hedge fund called Baker Brothers disclosed a 22.6% ownership stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

ACADIA Pharmaceuticals Inc. (ACAD)

Baker Brothers History

Baker Brothers is a biotechnology-focused hedge fund that is owned by Julian and Felix Baker.  The hedge fund is widely admired by investors because of its huge investment returns, most notably from its early investments in Pharmacyclics, Inc. (NASDAQ:PCYC) and Seattle Genetics, Inc. (NASDAQ:SGEN).

Pharmacyclics, Inc. (NASDAQ:PCYC) is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.  The company has soared over the past 2 years, climbing from a low of under $8.00 to a high of $93.99.

Baker Brothers started adding shares of Pharmacyclics back in the fall of 2011 and have been increasing their stake since.  The company currently makes up 23% of the Baker Brothers portfolio and is worth approximately $878.4 million.  And while Pharmacyclics was an impressive investment, it wasn’t the only for the Baker Brothers.

Seattle Genetics, Inc. (NASDAQ:SGEN) is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer.  Seattle Genetics’ share price has soared since 2010.

The Baker Brothers started adding shares of Seattle Genetics back in 2010 and continued adding shares as the share price increased.  The company currently makes up 18% of the Baker Brothers portfolio and is worth approximately $686 million.  Clearly the Baker Brothers have a strong record of success, which is carrying over to their recent investment, Acadia Pharmaceuticals (NASDAQ:ACAD).

Acadia Pharmaceuticals

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.  The company has a deep pipeline of drug candidates led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson’s disease psychosis.  ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s pipeline also includes clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. (NYSE:AGN).  Below is a chart diagram showing the full pipeline for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), along with each product’s progress.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!